標(biāo)題: Titlebook: Exscalate4CoV; High-Performance Com Silvano Coletti,Gabriella Bernardi Book 2023 The Editor(s) (if applicable) and The Author(s), under exc [打印本頁(yè)] 作者: Fillmore 時(shí)間: 2025-3-21 18:33
書(shū)目名稱(chēng)Exscalate4CoV影響因子(影響力)
作者: Vulnerary 時(shí)間: 2025-3-21 20:57
The Drug Repurposing Strategy in the Exscalate4CoV Project: Raloxifene Clinical Trials,Cale smArt pLatform Against paThogEns for CoronaVirus (EXSCALATE4CoV; E4C), was used to identify drug candidates for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. E4C identified raloxifene as having great therapeutic potential, confirmed by in vitro data, which led to the p作者: 安撫 時(shí)間: 2025-3-22 04:11
The High-Performance Computing Resources for the EXSCALATE4CoV Project,n the case of a public health emergency, such as the ongoing coronavirus disease 2019 (COVID-19) pandemic, this identification needs to be accomplished quickly to support the rapid initiation of effective treatments to minimize casualties. The utilization of supercomputers, or more generally High-Pe作者: charisma 時(shí)間: 2025-3-22 04:52 作者: 主講人 時(shí)間: 2025-3-22 09:27 作者: cancellous-bone 時(shí)間: 2025-3-22 13:34
The Role of Structural Biology Task Force: Validation of the Binding Mode of Repurposed Drugs Againion, is a validated drug target for treating COVID-19. The structure of Mpro has been elucidated by macromolecular crystallography, but owing to its conformational flexibility, finding effective inhibitory ligands was challenging. Screening libraries of ligands as part of EXaSCale smArt pLatform Aga作者: cancellous-bone 時(shí)間: 2025-3-22 18:08 作者: 創(chuàng)作 時(shí)間: 2025-3-22 23:02
Exploiting Drug-Discovery Research for Educational Purposes,ience in society has become a role of science for society, underscoring the importance of effective communication in fostering scientific literacy. Informal science education experiences, facilitated by the more widespread implementation of information technologies, are becoming increasingly relevan作者: ascend 時(shí)間: 2025-3-23 02:14
Beyond the Exscalate4CoV Project: LIGATE and REMEDI4ALL Projects,rimary health and societal priority. At the same time, we became conscious that technological resources are often not used in the most efficient manner. The LIGATE and REpurposing MEDIcines For All (REMEDI4ALL) projects started on the large-scale mobilization efforts of the EXaSCale smArt pLatform A作者: Audiometry 時(shí)間: 2025-3-23 06:58
https://doi.org/10.1007/978-3-031-30691-4Exascale Computing; drug discovery; drug research against the Sars-Cov2; LIGATE project; SARS-CoV-2; mole作者: 該得 時(shí)間: 2025-3-23 10:35 作者: ELUDE 時(shí)間: 2025-3-23 14:58 作者: CHAFE 時(shí)間: 2025-3-23 19:07
Neonatal Intracranial Hemorrhage,Despite recent advancements, biopharma drug research and development remains expensive and time-consuming. However, there are numerous opportunities to build capabilities that enhance productivity and improve the probability of success.作者: 態(tài)學(xué) 時(shí)間: 2025-3-23 23:57 作者: 重畫(huà)只能放棄 時(shí)間: 2025-3-24 02:34 作者: Organonitrile 時(shí)間: 2025-3-24 07:39 作者: defuse 時(shí)間: 2025-3-24 13:25 作者: 過(guò)時(shí) 時(shí)間: 2025-3-24 15:33
C. Defilippi,B. Santoro,P. Pautassoce initiatives. The EXaSCale smArt pLatform Against paThogEns for CoronaVirus (EXSCALATE4CoV) consortium, led by Dompé farmaceutici S.p.A., brought together 18 global organizations to counter international pandemics more rapidly and efficiently. The consortium also partnered with Nanome, an extended作者: Protein 時(shí)間: 2025-3-24 22:17 作者: Basal-Ganglia 時(shí)間: 2025-3-25 00:52 作者: Precursor 時(shí)間: 2025-3-25 07:13 作者: Pillory 時(shí)間: 2025-3-25 11:32
Pasquale Paolantonio,Clarisse Dromainience in society has become a role of science for society, underscoring the importance of effective communication in fostering scientific literacy. Informal science education experiences, facilitated by the more widespread implementation of information technologies, are becoming increasingly relevan作者: Sarcoma 時(shí)間: 2025-3-25 15:22
Imaging of Iatrogenic Spinal Infection,rimary health and societal priority. At the same time, we became conscious that technological resources are often not used in the most efficient manner. The LIGATE and REpurposing MEDIcines For All (REMEDI4ALL) projects started on the large-scale mobilization efforts of the EXaSCale smArt pLatform A作者: invulnerable 時(shí)間: 2025-3-25 16:36
978-3-031-30690-7The Editor(s) (if applicable) and The Author(s), under exclusive license to Springer Nature Switzerl作者: 圓木可阻礙 時(shí)間: 2025-3-25 23:17 作者: 不利 時(shí)間: 2025-3-26 02:04 作者: textile 時(shí)間: 2025-3-26 06:21 作者: BOGUS 時(shí)間: 2025-3-26 12:14 作者: innovation 時(shí)間: 2025-3-26 14:23 作者: Evolve 時(shí)間: 2025-3-26 17:28 作者: infarct 時(shí)間: 2025-3-27 00:52 作者: ingrate 時(shí)間: 2025-3-27 02:30
Book 2023ising safe in man drugs for immediate treatment of the already infected population and then novel pan-coronavirus inhibitors to address future emergencies...This ambitious goal exploited a “chemical library” of 500 billion molecules, thanks to a processing capacity of more than 3 million molecules p作者: ARIA 時(shí)間: 2025-3-27 08:13
2191-530X n novel pan-coronavirus inhibitors to address future emergencies...This ambitious goal exploited a “chemical library” of 500 billion molecules, thanks to a processing capacity of more than 3 million molecules p978-3-031-30690-7978-3-031-30691-4Series ISSN 2191-530X Series E-ISSN 2191-5318 作者: 柏樹(shù) 時(shí)間: 2025-3-27 09:50 作者: 斗爭(zhēng) 時(shí)間: 2025-3-27 14:35 作者: 殘酷的地方 時(shí)間: 2025-3-27 20:04
C. Defilippi,B. Santoro,P. Pautassoal screening, docking, and other computational procedures. Nanome provided analysis of those computational procedures and supplied virtual reality headsets to help scientists better understand and interact with the molecular dynamics and key chemical interactions of SARS-CoV-2. Nanome’s collaborativ作者: 防銹 時(shí)間: 2025-3-27 23:53 作者: 膠水 時(shí)間: 2025-3-28 04:17 作者: Graduated 時(shí)間: 2025-3-28 07:42 作者: DUST 時(shí)間: 2025-3-28 14:09 作者: 青少年 時(shí)間: 2025-3-28 17:02 作者: Relinquish 時(shí)間: 2025-3-28 22:22 作者: 包庇 時(shí)間: 2025-3-29 01:13 作者: Chivalrous 時(shí)間: 2025-3-29 07:08 作者: dermatomyositis 時(shí)間: 2025-3-29 07:49 作者: 任命 時(shí)間: 2025-3-29 15:26
